세계 척추측만증 시장 – 2023-2030

Global Kyphoscoliosis Market - 2023-2030

상품코드PH6790
발행기관DataM Intelligence
발행일2023.09.06
페이지 수186 Pages
포맷PDF + EXCEL
커버리지Global

6,525,00011,775,000

보고서 요약(국문)

개요
전 세계 척추측만증 시장은 2022년 29억 달러에 달했으며, 2023년부터 2030년까지 연평균 5.1%의 성장률을 보이며 2030년에는 42억 달러에 이를 것으로 예상됩니다.
척추측만증은 척추가 두 평면, 즉 관상면(좌우)과 시상면(앞뒤)에서 비정상적으로 휘어지는 질환입니다. 이는 척추측만증과 척추후만증이 복합적으로 나타나는 척추 이상입니다. 척추측만증은 관상면에서 비정상적인 곡률을 유발하여 척추가 수평으로 휘어지게 합니다.
척추후만증은 시상면에서 척추가 앞뒤로 잘못 비틀어지면서 등이 굽거나 처지게 보이는 증상을 유발합니다. 3D 프린팅 및 컴퓨터 지원 설계(CAD) 기술을 활용한 환자 맞춤형 임플란트 및 수술 계획 도구 개발은 각 환자에게 맞는 수술을 시행함으로써 수술 결과를 개선할 수 있습니다. 치료 옵션으로는 물리 치료, 보조기 착용, 그리고 심한 경우 수술이 있습니다. 이러한 시술은 불편함을 줄이는 동시에 자세와 운동성을 개선하는 것을 목표로 합니다.
동향
신경계 질환의 증가
신경계 질환은 근육 조절, 협응력 및 전반적인 신경근 기능에 영향을 미치기 때문에 척추측만증의 발병 및 진행에 쉽게 영향을 줄 수 있습니다. 근육 위축증 및 척수근육위축증을 포함한 신경계 질환은 흔히 근력 약화를 동반합니다. 약해진 근육은 척추가 자연스러운 자세와 곡선을 유지하는 데 필요한 지지력을 제공하지 못합니다. 이러한 근력 약화로 인해 척추측만증과 같은 비정상적인 척추 곡선이 발생할 수 있습니다.
척수 종양이나 외상과 같은 일부 신경계 질환은 척수를 직접 압박하거나 손상시킬 수 있습니다. 근육 기능과 자세를 조절하는 정상적인 뇌 신호 전달을 방해함으로써 이러한 압박은 척추측만증과 같은 척추 이상을 유발할 가능성이 있습니다. 따라서 신경계 질환의 증가는 시장 성장을 촉진할 것입니다.

예를 들어, 최근 유엔 보고서에 따르면 전 세계 인구의 거의 6분의 1에 해당하는 최대 10억 명이 편두통, 뇌 손상, 신경 감염을 비롯하여 알츠하이머병, 파킨슨병, 뇌졸중, 다발성 경화증, 간질과 같은 신경계 질환을 앓고 있습니다. 매년 680만 명이 이러한 질병으로 고통받고 있습니다. 따라서 신경계 질환의 증가는 시장의 급속한 성장에 기여하고 있습니다.
치료 분야의 기술 발전
척추측만증의 진단, 치료 및 관리는 모두 기술 발전의 혜택을 크게 받았습니다. 이러한 발전은 질환에 대한 이해를 높이고 진단 능력을 향상시키며 더 나은 치료 옵션을 제공했습니다.
예를 들어, 특히 척추 수술에서 흔히 사용되는 의료 기기는 MAGEC 시스템입니다. 척추측만증의 진행을 늦추기 위해 성장기 동안 척추를 고정합니다. 소아 환자가 이 치료를 받는 환자의 상당 부분을 차지합니다. 2020년 2월 13일, MAGEC 시스템 모델 X 로드의 액추에이터 엔드 캡이 이식 후 분리되는 현상에 대한 불만 제기에 따라 안전 경고가 발표되었습니다. 데이터 평가 결과, 액추에이터 엔드 캡 분리 현상이 약 0.5%의 기기에서 발생한 것으로 나타나, 의료진은 모든 시스템 이식 시술을 중단했습니다.
의료진은 엔드 캡이 분리된 후 임플란트가 헐거워지거나, 부식되거나, 이동하거나, 통증을 유발할 수 있으며, 로드가 내부 보조기 역할을 하면서 계속 늘어나거나 벌어질 수 있다는 점에 유의해야 합니다. 이로 인해 액추에이터의 내부 부품이 노출되어 열화가 가속화되고, 티타늄 합금, 마모 파편, 국소 조직 변색 등이 시스템 내부로 유입될 수 있습니다.
치료 관련 부작용
척추측만증은 질환의 심각도와 환자의 특정 요구에 따라 보조기 착용, 물리 치료, 수술 등 다양한 방법으로 치료할 수 있습니다. 각 치료법에는 몇 가지 잠재적인 부작용과 고려 사항이 있습니다. 장기간 보조기를 착용하면 피부 발진, 마찰 또는 압박 궤양이 발생할 수 있습니다.
패드를 사용하고 보조기를 제대로 착용하면 이러한 문제를 완화할 수 있습니다. 물리 치료 운동, 특히 새로운 운동을 시작할 때는 근육통이 발생할 수 있습니다. 환자는 수술 후 몇 주 또는 몇 달 동안 수술 부위에 통증과 불편함을 느낄 수 있습니다. 통증 관리는 수술 후 관리에서 매우 중요한 부분입니다.
보고서에 대한 자세한 내용은 샘플을 요청하십시오.
세그먼트 분석
전 세계 척추측만증 시장은 유형, 질병 관리, 연령대, 최종 사용자 및 지역별로 세분화됩니다.
척추측만증은 성인보다 어린이에게 더 쉽게 발생할 수 있습니다.
척추측만증은 소아 및 청소년기에 발달하는 척추와 근골격계와 관련된 여러 문제로 인해 성인보다 어린이에게 더 쉽게 발생할 수 있습니다. 예를 들어, 일부 어린이는 선천성 척추 이상으로 인해 척추측만증이 발생할 위험이 더 높습니다. 이러한 이상은 아이의 척추가 성장하고 발달하기 시작할 때까지 발견되지 않을 수 있습니다.

척추를 둘러싼 인대와 연조직은 어린이와 청소년기에 빠르게 성장합니다. 이러한 구조가 제대로 발달하지 않거나 성장 속도가 다를 경우 척추측만증이 발생할 수 있습니다. 어린이와 청소년은 척추에 과도한 부담을 주는 활동에 참여하거나 잘못된 자세 습관을 가질 가능성이 더 높습니다. 큰 배낭을 메거나, 구부정한 자세로 장시간 전자기기를 사용하거나, 잘못된 자세로 여러 가지 작업을 수행하는 것은 척추에 무리를 주어 척추측만증을 유발할 수 있습니다. 따라서 이러한 모든 요인이 척추측만증의 확산을 가속화하는 데 기여합니다.
지리적 확산
북미 지역의 제품 승인 증가 및 질병 유병률 증가
역사적, 경제적, 사회적 요인이 복합적으로 작용하여 북미, 특히 미국과 캐나다에서 의료 서비스가 크게 발전했습니다. 북미에서는 미국과 캐나다의 식품의약국(FDA)과 같은 규제 기관이 의약품 및 의료기기의 효능과 안전성에 대한 엄격한 지침을 설정합니다. 이러한 기관들은 안전하고 효과적인 의약품만 유통되도록 보장합니다.

또한, 북미에는 수많은 의학 연구 기관, 학술 기관 및 의료 시설이 척추 관련 연구의 최전선에 있습니다. 척추측만증의 원인, 위험 요인 및 이용 가능한 치료법에 대해 더 자세히 알아보기 위해 이 지역 연구자들은 활발히 연구를 진행하고 있습니다. 이러한 연구 관심 분야로 인해 임상 시험이 필수적입니다. 북미는 선진적인 의료 시스템과 의료 기술 덕분에 임상 시험을 수행하기에 최적의 장소입니다. 현대적인 시설, 자격을 갖춘 의료진 및 첨단 영상 기술을 활용하여 임상 연구를 수행할 수 있습니다. 따라서 이러한 모든 요소들이 이 지역의 성장에 기여하고 있습니다.

코로나19 영향 분석
많은 의료 시스템은 팬데믹 기간 동안 척추측만증의 진단 및 치료를 포함한 비응급 진료에 차질과 지연을 겪었습니다. 여러 지역에서 정기 검사, 영상 검사 및 선택적 치료가 연기되거나 취소되어 일부 환자의 진단 및 치료가 지연되었습니다.

척추측만증 치료를 위해 정형외과용 보조기에 의존하는 환자들은 병원 서비스가 축소되거나 봉쇄 조치가 시행되는 동안 보조기 착용, 조정 또는 교체에 어려움을 겪었을 수 있습니다. 이는 보조기 치료의 효과에 영향을 미칠 수 있습니다. 코로나19 감염이 심각한 시기에는 의료 서비스 비용을 절감하고 병원 내 바이러스 전파 위험을 줄이기 위해 척추측만증 치료와 같은 선택적 치료가 일상적으로 연기되었습니다. 결과적으로 수술이 필요한 환자들은 더 오래 기다려야 했을 수 있습니다.
유형별
• 척추측만증
• 척추후만증
o 자세성 척추후만증
o 슈어만 척추후만증
o 연령성 척추후만증
o 선천성 척추후만증
질병 관리별
• 진단
o MRI
o CT 스캔
o 골밀도 검사
o 기타
• 약물 치료
• 수술
o 척추 임플란트
o 골 이식
o 보조기 및 교정기
o 기타
연령대별
• 어린이
• 성인
최종 사용자별
• 병원
• 클리닉
• 외래 수술 센터
지역별
• 북미
o 미국
o 캐나다
o 멕시코
• 유럽
o 독일
o 영국
o 프랑스
o 이탈리아
o 스페인
o 기타 유럽
• 남미
o 브라질
o 아르헨티나
o 기타 남미
• 아시아 태평양
o 중국
o 인도
o 일본
o 호주
o 기타 아시아 태평양
• 중동 및 아프리카
범례 최근 동향
• 2022년 7월 5일, 인도 최고의 종합병원인 SIMS 병원의 숙련된 외과의사 팀이 심각한 척추측만증 환자를 치료하기 위한 고난도 수술을 성공적으로 시행했습니다. 척추 외과계에서는 심각한 척추측만증을 앓고 있는 15세 에티오피아 환자 테스파예 멩게샤 메르샤(Tesfaye Mengesha Mersha)를 "아나콘다 척추"라고 부르는데, 이는 흉부 상부 척추가 110도까지 굽은 변형을 의미합니다.

• 세계적인 의료 기술 기업인 메드트로닉(Medtronic plc)에 따르면, 2021년 9월 22일, 진행성 소아 특발성 척추측만증(JIS) 또는 청소년 특발성 척추측만증(AIS) 치료를 위한 Braive™ 성장 조절 시스템의 안전성과 효능을 평가하는 BRAIVE IDE 연구의 첫 번째 수술이 완료되었습니다.

경쟁 환경
시장의 주요 글로벌 업체로는 Koninklijke Philips N.V., Canon, GE Healthcare, Siemens, Hologic, Sri Krishna Pharmaceuticals Ltd, NEXGEN PHARMA INC, ValiantLabs.in, BASF Corporation, Dr. Reddy’s Laboratories Ltd 등이 있습니다.
보고서 ​​구매 이유

• 유형, 질병 관리, 연령대, 최종 사용자 및 지역별 글로벌 척추측만증 시장 세분화를 시각화하고 주요 상업 자산 및 업체를 파악합니다.

• 트렌드 분석 및 공동 개발을 통해 사업 기회를 모색합니다.

• 모든 세그먼트를 포함한 척추측만증 시장 수준의 다양한 데이터가 담긴 Excel 데이터 시트를 제공합니다.

• 심층적인 질적 인터뷰와 연구를 바탕으로 종합적인 분석 결과를 담은 PDF 보고서를 제공합니다.

• 모든 주요 업체의 핵심 제품을 포함하는 제품 맵핑 Excel 파일을 제공합니다.

글로벌 척추측만증 시장 보고서는 약 61개의 표, 58개의 그림, 그리고 186페이지 분량으로 구성될 예정입니다.
주요 대상 고객 (2023년 기준)
• 제조업체/구매자
• 산업 투자자/투자은행가
• 시장 조사 전문가
• 신흥 기업

보고서 요약(영어 원문)

Overview
Global Kyphoscoliosis Market reached US$ 2.9 billion in 2022 and is expected to reach US$ 4.2 billion by 2030, growing with a CAGR of 5.1% during the forecast period 2023-2030.
Kyphoscoliosis is an abnormal curve of the spine on two planes: the coronal plane, or side to side, and the sagittal plane, or back to front. It’s a combined spinal abnormality of two other conditions: kyphosis and scoliosis. Scoliosis causes an abnormal coronal plane curvature, which causes the spine to curve horizontally.
By improperly twisting forward or backward on the sagittal plane, kyphosis causes the back to seem rounded or fell. The development of patient-specific implants and surgical planning tools, typically assisted by 3D printing and computer-assisted design, can improve surgical outcomes by customising operations for each patient. Treatment options include physical therapy, bracing, and in severe situations, surgery. These procedures aim to reduce discomfort while also improving posture and mobility.
Dynamics
The Rise of Neurological Disorders
Neurological disorders can easily influence the onset and evolution of kyphoscoliosis due to their effects on muscle control, coordination, and general neuromuscular function. Neurological diseases including muscular dystrophy and spinal muscular atrophy frequently present with muscle weakness. Weak muscles are unable to provide the spine with the necessary support to maintain its natural posture and curvature. Atypical spinal curvatures, such kyphoscoliosis, may arise as a result of this weakening.
Some neurological conditions, such as spinal cord tumours or trauma, can directly compress the spinal cord or injure it. By interfering with the regular brain impulses that control muscle function and posture, this compression has the potential to result in spinal anomalies such kyphoscoliosis. Therefore, the increase of neurological disorders will boost market growth.
For instance, according to a recent United Nations report, up to 1 billion people, or nearly one in six of the world's population, suffer from neurological disorders, including migraine, brain injuries, and neuroinfections as well as diseases like Alzheimer's and Parkinson's, stroke, multiple sclerosis, and epilepsy. Each year, 6.8 million people suffer as a result of these illnesses. Thus, the rise in neurological conditions contributes to the market's rapid expansion.
Technological Advancements in the Treatment
The diagnosis, treatment, and management of kyphoscoliosis have all benefited greatly from technological improvements. These developments have increased our understanding of the disorder, improved the capacity to diagnose it, and provided better therapy options.
For instance, a common medical device, particularly in spinal surgery, is the MAGEC system. In order to slow the progression of scoliosis, the spine is braced during growth. Paediatric patients make up a large portion of the patients receiving this treatment. A safety notice was issued on February 13, 2020, in response to complaints of post-implantation separation of an actuator end cap in MAGEC system Model X rods. The data evaluation revealed that the actuator end cap separation had happened in about 0.5% of the devices, prompting doctors to stop all system implantations.
Physicians have been cautioned that after the end cap has separated, the implant may become loose, corrode, migrate, or cause pain, and that the rod may continue to extend or distract while acting as an internal brace. This could result in the actuator's internal components becoming exposed, which could speed their deterioration and allow titanium alloy, wear debris, and localised tissue discoloration to enter the system.
Side Effects Associated with the Treatment
Kyphoscoliosis can be treated in a number of ways, including bracing, physical therapy, and surgery, depending on the severity of the condition and the patient's specific needs. There are several potential side effects and considerations specific to each form of treatment. An extended period of wearing a brace may result in skin rashes, chafing, or pressure sores.
Padding and a proper fit could mitigate this issue. Physical therapy exercises may cause muscle soreness, especially when starting a new exercise routine. Patients may experience pain and discomfort at the surgical site for several weeks or months after the procedure. Pain control is a crucial part of postoperative care.
For more details of the report, Request for sample
Segment Analysis
The global kyphoscoliosis market is segmented based on type, disease management, age group, end user and region.
Kyphoscoliosis can Affect Children more Easily than Adults
Kyphoscoliosis can affect children more easily than adults due to a number of issues associated to the developing spine and musculoskeletal system during childhood and adolescence. For instance, certain children have a higher risk of developing kyphoscoliosis due to congenital spine abnormalities. These anomalies might not be identified until the child's spine begins to grow and develop.
The ligaments and soft tissues that surround the spine also grow swiftly in children and teenagers. These structures may not develop properly or expand at different rates, which can cause kyphoscoliosis. Children and teenagers are more likely to participate in activities that strain the spine excessively or adopt poor postural habits. Large backpacks, protracted use of electronic gadgets while hunched over, and various badly performed tasks can strain the spine and possibly result in kyphoscoliosis. Thus, all of those factors contribute to accelerating segment expansion.
Geographical Penetration
Rising Product Approvals and Prevalence of Disease in the North American Region
A mix of historical, economic, and societal factors have contributed to the great advancement of healthcare services in North America, especially in the United States and Canada. In North America, regulatory organisations like the Food and Drug Administration (FDA) in the United States and Canada set strict guidelines for the effectiveness and safety of medications and medical devices. These organisations aid in ensuring that only secure and efficient medications are distributed.
Moreover, numerous medical research organisations, academic institutes, and healthcare facilities located in North America are at the forefront of spine-related research. To learn more about the origins, risk factors, and available treatments for kyphoscoliosis, researchers in the area are actively researching the condition. Clinical trials are required because of this area of research interest. North America is the perfect site for conducting clinical trials due to its sophisticated healthcare system and medical technologies. Clinical research can be carried out with the help of modern facilities, qualified medical personnel, and advanced imaging technology. Thus, all of these variables contribute to the region's growth.
COVID-19 Impact Analysis
Many healthcare systems had issues and delays in non-urgent care during the pandemic, including the diagnosis and treatment of kyphoscoliosis. Routine tests, imaging, and elective treatments were postponed or cancelled in a number of locations, which would have delayed the diagnosis and treatment of some patients.
Patients who rely on orthopaedic braces for their kyphoscoliosis therapy may have experienced difficulties getting their braces fitted, adjusted, or replaced when hospitals cut back on their services or during lockdowns. This could impact the effectiveness of bracing therapies. During periods of high COVID-19 activity, elective treatments, such as those to treat kyphoscoliosis, were routinely delayed to save money on medical services and reduce the risk of viral transmission in hospitals. As a result, individuals who require surgery could have to wait longer.
By Type
• Scoliosis
• Kyphosis
o Postural kyphosis
o Scheuermann’s kyphosis
o Age-related kyphosis
o Congenital kyphosis
By Disease Management
• Diagnosis
o MRI
o CT Scan
o Bone Density Testing
o Others
• Medication
• Surgery
o Spinal Implants
o Bone Grafts
o Braces and Orthotics
o Others
By Age Group
• Children
• Adults
By End User
• Hospitals
• Clinics
• Ambulatory Surgical Centers
By Region
• North America
o U.S.
o Canada
o Mexico
• Europe
o Germany
o UK
o France
o Italy
o Spain
o Rest of Europe
• South America
o Brazil
o Argentina
o Rest of South America
• Asia-Pacific
o China
o India
o Japan
o Australia
o Rest of Asia-Pacific
• Middle East and Africa
Key Developments
• On July 05, 2022, an advanced surgery was recently performed by a skilled team of surgeons from the city's top multispecialty hospital, SIMS Hospital India, to treat a severe case of kyphoscoliosis. The spine surgery community refers to the 15-year-old Ethiopian patient, Master Tesfaye Mengesha Mersha, who has severe kyphoscoliosis, as having a "Anaconda Spine," a 110-degree deformity of the upper spine in the chest area.
• On September 22, 2021, the first surgical procedure in the BRAIVE IDE study, which will assess the safety and efficacy of the BraiveTM growth modulation system for the treatment of progressive juvenile (JIS) or adolescent (AIS) idiopathic scoliosis, has been completed, according to Medtronic plc, the world leader in medical technology.
Competitive Landscape
The major global players in the market include Koninklijke Philips N.V., Canon, GE Healthcare, Siemens, Hologic, Sri Krishna Pharmaceuticals Ltd, NEXGEN PHARMA INC, ValiantLabs.in., BASF Corporation, Dr. Reddy’s Laboratories Ltd and among others.
Why Purchase the Report?
• To visualize the global kyphoscoliosis market segmentation based on type, disease management, age group, end user and region as well as understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development.
• Excel data sheet with numerous data points of kyphoscoliosis market-level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping available as excel consisting of key products of all the major players.
The global kyphoscoliosis market report would provide approximately 61 tables, 58 figures and 186 Pages.
Target Audience 2023
• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies

상세 목차

1. Methodology and Scope
1.1. Research Methodology
1.2. Research Objective and Scope of the Report
2. Definition and Overview
3. Executive Summary
3.1. Snippet by Type
3.2. Snippet by Disease Management
3.3. Snippet by Age Group
3.4. Snippet by End User
3.5. Snippet by Region
4. Dynamics
4.1. Impacting Factors
4.1.1. Drivers
4.1.1.1. The rise of Neurological disorders
4.1.1.2. Technological advancements in the Treatment
4.2. Restraints
4.2.1.1. Side effects associated with the treatment
4.2.2. Opportunity
4.2.3. Impact Analysis
5. Industry Analysis
5.1. Porter's Five Force Analysis
5.2. Supply Chain Analysis
5.3. Pricing Analysis
5.4. Regulatory Analysis
5.5. Russia-Ukraine War Impact Analysis
5.6. DMI Opinion
6. COVID-19 Analysis
6.1. Analysis of COVID-19
6.1.1. Scenario Before COVID
6.1.2. Scenario During COVID
6.1.3. Scenario Post COVID
6.2. Pricing Dynamics Amid COVID-19
6.3. Demand-Supply Spectrum
6.4. Government Initiatives Related to the Market During Pandemic
6.5. Manufacturers Strategic Initiatives
6.6. Conclusion
7. By Type
7.1. Introduction
7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
7.1.2. Market Attractiveness Index, By Type
7.2. Scoliosis *
7.2.1. Introduction
7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
7.3. Kyphosis
7.3.1. Postural kyphosis
7.3.2. Scheuermann’s kyphosis
7.3.3. Age-related kyphosis
7.3.4. Congenital kyphosis
8. By Disease Management
8.1. Introduction
8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Management
8.1.2. Market Attractiveness Index, By Disease Management
8.2. Diagnosis*
8.2.1. Introduction
8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
8.2.2.1. MRI
8.2.2.2. CT Scan
8.2.2.3. Bone Density Testing
8.2.2.4. Others
8.3. Medication
8.4. Surgery
8.4.1. Spinal Implants
8.4.2. Bone Grafts
8.4.3. Braces and Orthotics
8.4.4. Others
9. By Age Group
9.1. Introduction
9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Age Group
9.1.2. Market Attractiveness Index, By Age Group
9.2. Children*
9.2.1. Introduction
9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
9.3. Adults
10. By End User
10.1. Introduction
10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
10.1.2. Market Attractiveness Index, By End User
10.2. Hospitals*
10.2.1. Introduction
10.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
10.3. Clinics
10.4. Ambulatory Surgical Centres
11. By Region
11.1. Introduction
11.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
11.1.2. Market Attractiveness Index, By Region
11.2. North America
11.2.1. Introduction
11.2.2. Key Region-Specific Dynamics
11.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
11.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
11.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End Users
11.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
11.2.6.1. U.S.
11.2.6.2. Canada
11.2.6.3. Mexico
11.3. Europe
11.3.1. Introduction
11.3.2. Key Region-Specific Dynamics
11.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
11.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Management
11.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Age Group
11.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
11.3.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
11.3.7.1. Germany
11.3.7.2. UK
11.3.7.3. France
11.3.7.4. Italy
11.3.7.5. Spain
11.3.7.6. Rest of Europe
11.4. South America
11.4.1. Introduction
11.4.2. Key Region-Specific Dynamics
11.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
11.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Management
11.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Age Group
11.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
11.4.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
11.4.7.1. Brazil
11.4.7.2. Argentina
11.4.7.3. Rest of South America
11.5. Asia-Pacific
11.5.1. Introduction
11.5.2. Key Region-Specific Dynamics
11.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
11.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Management
11.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Age Group
11.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
11.5.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
11.5.7.1. China
11.5.7.2. India
11.5.7.3. Japan
11.5.7.4. Australia
11.5.7.5. Rest of Asia-Pacific
11.6. Middle East and Africa
11.6.1. Introduction
11.6.2. Key Region-Specific Dynamics
11.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
11.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Management
11.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Age Group
11.6.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
12. Competitive Landscape
12.1. Competitive Scenario
12.2. Market Positioning/Share Analysis
12.3. Mergers and Acquisitions Analysis
13. Company Profiles (1-5 Diagnosis Device Manufacturers & 6-10 Drug Manufacturers)
13.1. Koninklijke Philips N.V. *
13.1.1. Company Overview
13.1.2. Product Portfolio and Description
13.1.3. Financial Overview
13.1.4. Key Developments
13.2. Canon
13.3. GE Healthcare
13.4. Siemens
13.5. Hologic
13.6. Sri Krishna Pharmaceuticals Ltd
13.7. NEXGEN PHARMA INC
13.8. ValiantLabs.in.
13.9. BASF Corporation
13.10. Dr. Reddy’s Laboratories Ltd
LIST NOT EXHAUSTIVE
14. Appendix
14.1. About Us and Services
14.2. Contact Us

언급된 주요 기업들

Koninklijke Philips N.V., 4. Key Developments, Canon, GE Healthcare, Siemens, Hologic, Sri Krishna Pharmaceuticals Ltd, NEXGEN PHARMA INC, ValiantLabs.in., BASF Corporation, Dr. Reddy’s Laboratories Ltd

표 목록 (Tables)

List of Tables

Table 1 Global Kyphoscoliosis Market Value, By Type, 2022, 2026 & 2030 (US$ Billion)

Table 2 Global Kyphoscoliosis Market Value, By Disease Management, 2022, 2026 & 2030 (US$ Billion)

Table 3 Global Kyphoscoliosis Market Value, By Age Group, 2022, 2026 & 2030 (US$ Billion)

Table 4 Global Kyphoscoliosis Market Value, By End User, 2022, 2026 & 2030 (US$ Billion)

Table 5 Global Kyphoscoliosis Market Value, By Region, 2022, 2026 & 2030 (US$ Billion)

Table 6 Global Kyphoscoliosis Market Value, By Type, 2022, 2026 & 2030 (US$ Billion)

Table 7 Global Kyphoscoliosis Market Value, By Type, 2021-2030 (US$ Billion)

Table 8 Global Kyphoscoliosis Market Value, By Disease Management, 2022, 2026 & 2030 (US$ Billion)

Table 9 Global Kyphoscoliosis Market Value, By Disease Management, 2021-2030 (US$ Billion)

Table 10 Global Kyphoscoliosis Market Value, By Age Group, 2022, 2026 & 2030 (US$ Billion)

Table 11 Global Kyphoscoliosis Market Value, By Age Group, 2021-2030 (US$ Billion)

Table 12 Global Kyphoscoliosis Market Value, By End User, 2022, 2026 & 2030 (US$ Billion)

Table 13 Global Kyphoscoliosis Market Value, By End User, 2021-2030 (US$ Billion)

Table 14 Global Kyphoscoliosis Market Value, By Region, 2022, 2026 & 2030 (US$ Billion)

Table 15 Global Kyphoscoliosis Market Value, By Region, 2021-2030 (US$ Billion)

Table 16 North America Kyphoscoliosis Market Value, By Type, 2021-2030 (US$ Billion)

Table 17 North America Kyphoscoliosis Market Value, By Disease Management, 2021-2030 (US$ Billion)

Table 18 North America Kyphoscoliosis Market Value, By Age Group, 2021-2030 (US$ Billion)

Table 19 North America Kyphoscoliosis Market Value, By End User, 2021-2030 (US$ Billion)

Table 20 North America Kyphoscoliosis Market Value, By Country, 2021-2030 (US$ Billion)

Table 21 South America Kyphoscoliosis Market Value, By Type, 2021-2030 (US$ Billion)

Table 22 South America Kyphoscoliosis Market Value, By Disease Management, 2021-2030 (US$ Billion)

Table 23 South America Kyphoscoliosis Market Value, By Age Group, 2021-2030 (US$ Billion)

Table 24 South America Kyphoscoliosis Market Value, By End User, 2021-2030 (US$ Billion)

Table 25 South America Kyphoscoliosis Market Value, By Country, 2021-2030 (US$ Billion)

Table 26 Europe Kyphoscoliosis Market Value, By Type, 2021-2030 (US$ Billion)

Table 27 Europe Kyphoscoliosis Market Value, By Disease Management, 2021-2030 (US$ Billion)

Table 28 Europe Kyphoscoliosis Market Value, By Age Group, 2021-2030 (US$ Billion)

Table 29 Europe Kyphoscoliosis Market Value, By End User, 2021-2030 (US$ Billion)

Table 30 Europe Kyphoscoliosis Market Value, By Country, 2021-2030 (US$ Billion)

Table 31 Asia-Pacific Kyphoscoliosis Market Value, By Type, 2021-2030 (US$ Billion)

Table 32 Asia-Pacific Kyphoscoliosis Market Value, By Disease Management, 2021-2030 (US$ Billion)

Table 33 Asia-Pacific Kyphoscoliosis Market Value, By Age Group, 2021-2030 (US$ Billion)

Table 34 Asia-Pacific Kyphoscoliosis Market Value, By End User, 2021-2030 (US$ Billion)

Table 35 Asia-Pacific Kyphoscoliosis Market Value, By Country, 2021-2030 (US$ Billion)

Table 36 Middle East & Africa Kyphoscoliosis Market Value, By Type, 2021-2030 (US$ Billion)

Table 37 Middle East & Africa Kyphoscoliosis Market Value, By Disease Management, 2021-2030 (US$ Billion)

Table 38 Middle East & Africa Kyphoscoliosis Market Value, By Age Group, 2021-2030 (US$ Billion)

Table 39 Middle East & Africa Kyphoscoliosis Market Value, By End User, 2021-2030 (US$ Billion)

Table 40 Koninklijke Philips N.V.: Overview

Table 41 Koninklijke Philips N.V.: Product Portfolio

Table 42 Koninklijke Philips N.V.: Key Developments

Table 43 Canon: Overview

Table 44 Canon: Product Portfolio

Table 45 Canon: Key Developments

Table 46 GE Healthcare: Overview

Table 47 GE Healthcare: Product Portfolio

Table 48 GE Healthcare: Key Developments

Table 49 Siemens: Overview

Table 50 Siemens: Product Portfolio

Table 51 Siemens: Key Developments

Table 52 Hologic: Overview

Table 53 Hologic: Product Portfolio

Table 54 Hologic: Key Developments

Table 55 Sri Krishna Pharmaceuticals Ltd : Overview

Table 56 Sri Krishna Pharmaceuticals Ltd : Product Portfolio

Table 57 Sri Krishna Pharmaceuticals Ltd : Key Developments

Table 58 NEXGEN PHARMA INC: Overview

Table 59 NEXGEN PHARMA INC: Product Portfolio

Table 60 NEXGEN PHARMA INC: Key Developments

Table 61 ValiantLabs.in.: Overview

Table 62 ValiantLabs.in.: Product Portfolio

Table 63 ValiantLabs.in.: Key Developments

Table 64 BASF Corporation: Overview

Table 65 BASF Corporation: Product Portfolio

Table 66 BASF Corporation: Key Developments

Table 67 Dr. Reddy’s Laboratories Ltd: Overview

Table 68 Dr. Reddy’s Laboratories Ltd: Product Portfolio

Table 69 Dr. Reddy’s Laboratories Ltd: Key Developments

그림 목록 (Figures)

List of Figures

Figure 1 Global Kyphoscoliosis Market Value, 2021-2030 (US$ Billion)

Figure 2 Global Kyphoscoliosis Market Share, By Type, 2022 & 2030 (%)

Figure 3 Global Kyphoscoliosis Market Share, By Disease Management, 2022 & 2030 (%)

Figure 4 Global Kyphoscoliosis Market Share, By Age Group, 2022 & 2030 (%)

Figure 5 Global Kyphoscoliosis Market Share, By End User, 2022 & 2030 (%)

Figure 6 Global Kyphoscoliosis Market Share, By Region, 2022 & 2030 (%)

Figure 7 Global Kyphoscoliosis Market Y-o-Y Growth, By Type, 2022-2030 (%)

Figure 8 Scoliosis Kyphoscoliosis Market Value, 2021-2030 (US$ Billion)

Figure 9 Kyphosis Kyphoscoliosis Market Value, 2021-2030 (US$ Billion)

Figure 10 Global Kyphoscoliosis Market Y-o-Y Growth, By Disease Management, 2022-2030 (%)

Figure 11 Diagnosis Disease Management in Global Kyphoscoliosis Market Value, 2021-2030 (US$ Billion)

Figure 12 Medication Disease Management in Global Kyphoscoliosis Market Value, 2021-2030 (US$ Billion)

Figure 13 Surgery Disease Management in Global Kyphoscoliosis Market Value, 2021-2030 (US$ Billion)

Figure 14 Global Kyphoscoliosis Market Y-o-Y Growth, By Age Group, 2022-2030 (%)

Figure 15 Children Age Group in Global Kyphoscoliosis Market Value, 2021-2030 (US$ Billion)

Figure 16 Adults Age Group in Global Kyphoscoliosis Market Value, 2021-2030 (US$ Billion)

Figure 17 Global Kyphoscoliosis Market Y-o-Y Growth, By End User, 2022-2030 (%)

Figure 18 Hospitals End User in Global Kyphoscoliosis Market Value, 2021-2030 (US$ Billion)

Figure 19 Clinics End User in Global Kyphoscoliosis Market Value, 2021-2030 (US$ Billion)

Figure 20 Ambulatory Surgical Centres End User in Global Kyphoscoliosis Market Value, 2021-2030 (US$ Billion)

Figure 21 Global Kyphoscoliosis Market Y-o-Y Growth, By Region, 2022-2030 (%)

Figure 22 North America Kyphoscoliosis Market Value, 2021-2030 (US$ Billion)

Figure 23 Asia-Pacific Kyphoscoliosis Market Value, 2021-2030 (US$ Billion)

Figure 24 Europe Kyphoscoliosis Market Value, 2021-2030 (US$ Billion)

Figure 25 South America Kyphoscoliosis Market Value, 2021-2030 (US$ Billion)

Figure 26 Middle East and Africa Kyphoscoliosis Market Value, 2021-2030 (US$ Billion)

Figure 27 North America Kyphoscoliosis Market Value, 2021-2030 (US$ Billion)

Figure 28 North America Kyphoscoliosis Market Share, By Type, 2022 & 2030 (%)

Figure 29 North America Kyphoscoliosis Market Share, By Disease Management, 2022 & 2030 (%)

Figure 30 North America Kyphoscoliosis Market Share, By Age Group, 2022 & 2030 (%)

Figure 31 North America Kyphoscoliosis Market Share, By End User, 2022 & 2030 (%)

Figure 32 North America Kyphoscoliosis Market Share, By Country, 2022 & 2030 (%)

Figure 33 South America Kyphoscoliosis Market Value, 2021-2030 (US$ Billion)

Figure 34 South America Kyphoscoliosis Market Share, By Type, 2022 & 2030 (%)

Figure 35 South America Kyphoscoliosis Market Share, By Disease Management, 2022 & 2030 (%)

Figure 36 South America Kyphoscoliosis Market Share, By Age Group, 2022 & 2030 (%)

Figure 37 South America Kyphoscoliosis Market Share, By End User, 2022 & 2030 (%)

Figure 38 South America Kyphoscoliosis Market Share, By Country, 2022 & 2030 (%)

Figure 39 Europe Kyphoscoliosis Market Value, 2021-2030 (US$ Billion)

Figure 40 Europe Kyphoscoliosis Market Share, By Type, 2022 & 2030 (%)

Figure 41 Europe Kyphoscoliosis Market Share, By Disease Management, 2022 & 2030 (%)

Figure 42 Europe Kyphoscoliosis Market Share, By Age Group, 2022 & 2030 (%)

Figure 43 Europe Kyphoscoliosis Market Share, By End User, 2022 & 2030 (%)

Figure 44 Europe Kyphoscoliosis Market Share, By Country, 2022 & 2030 (%)

Figure 45 Asia-Pacific Kyphoscoliosis Market Value, 2021-2030 (US$ Billion)

Figure 46 Asia-Pacific Kyphoscoliosis Market Share, By Type, 2022 & 2030 (%)

Figure 47 Asia-Pacific Kyphoscoliosis Market Share, By Disease Management, 2022 & 2030 (%)

Figure 48 Asia-Pacific Kyphoscoliosis Market Share, By Age Group, 2022 & 2030 (%)

Figure 49 Asia-Pacific Kyphoscoliosis Market Share, By End User, 2022 & 2030 (%)

Figure 50 Asia-Pacific Kyphoscoliosis Market Share, By Country, 2022 & 2030 (%)

Figure 51 Middle East & Africa Kyphoscoliosis Market Value, 2021-2030 (US$ Billion)

Figure 52 Middle East & Africa Kyphoscoliosis Market Share, By Type, 2022 & 2030 (%)

Figure 53 Middle East & Africa Kyphoscoliosis Market Share, By Disease Management, 2022 & 2030 (%)

Figure 54 Middle East & Africa Kyphoscoliosis Market Share, By Age Group, 2022 & 2030 (%)

Figure 55 Middle East & Africa Kyphoscoliosis Market Share, By End User, 2022 & 2030 (%)

Figure 56 Koninklijke Philips N.V.: Financials

Figure 57 Canon: Financials

Figure 58 GE Healthcare: Financials

Figure 59 Siemens: Financials

Figure 60 Hologic: Financials

Figure 61 Sri Krishna Pharmaceuticals Ltd : Financials

Figure 62 NEXGEN PHARMA INC: Financials

Figure 63 ValiantLabs.in.: Financials

Figure 64 BASF Corporation: Financials

Figure 65 Dr. Reddy’s Laboratories Ltd: Financials